The prognostic classification of patients with
|
|
- Fay Norman
- 5 years ago
- Views:
Transcription
1 HEPATOLOGY, VOL. 67, NO. 6, 2018 AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOBILIARY MALIGNANCIES External Validation of the ITA.LI.CA Prognostic System for Patients With Hepatocellular Carcinoma: A Multicenter Cohort Study Mauro Borzio, 1 Elena Dionigi, 1 Angelo Rossini, 2 Massimo Marignani, 3 Rodolfo Sacco, 4 Ilario De Sio, 5 Emanuela Bertolini, 6 Giampiero Francica, 7 Anna Giacomin, 8 Giancarlo Parisi, 9 Susanna Vicari, 10 Anna Toldi, 11 Andrea Salmi, 12 Sergio Boccia, 13 Mario Mitra, 14 and Fabio Fornari 15 Several staging systems for hepatocellular carcinoma (HCC) have been developed. The Barcelona Clinic Liver Cancer staging system is considered the best in predicting survival, although limitations have emerged. Recently, the Italian Liver Cancer (ITA.LI.CA) prognostic system, integrating ITA.LI.CA tumor staging (stages 0, A, B1-3, C) with the Child-Turcotte-Pugh score, Eastern Cooperative Oncology Group performance status, and alpha-fetoprotein with a strong ability to predict survival, was proposed. The aim of our study was to provide an external validation of the ITA.LI.CA system in an independent real-life occidental cohort of HCCs. From September 2008 to April 2016, 1,508 patients with cirrhosis and incident HCC were consecutively enrolled in 27 Italian institutions. Clinical, tumor, and treatment-related variables were collected, and patients were stratified according to scores of the Barcelona Clinic Liver Cancer system, ITA.LI.CA prognostic system, Hong Kong Liver Cancer system, Cancer of the Liver Italian Program, Japanese Integrated System, and model to estimate survival in ambulatory patients with hepatocellular carcinoma. Harrell s C-index, Akaike information criterion, and likelihood-ratio test were used to compare the predictive ability of the different systems. A subgroup analysis for treatment category (curative versus palliative) was performed. Median follow-up was 44 months (interquartile range, months), and median overall survival was 34 months (interquartile range, months). Median age was 71 years, and patients were mainly male individuals and hepatitis C virus carriers. According to ITA.LI.CA tumor staging, 246 patients were in stage 0, 472 were in stage A, 657 were in stages B1/3, and 133 were in stage C. The ITA.LI.CA prognostic system showed the best discriminatory ability (C-index ) and monotonicity of gradients compared to other systems, and its superiority was also confirmed after stratification for treatment strategy. Conclusion: This is the first study that independently validated the ITA.LI.CA prognostic system in a large cohort of Western patients with incident HCCs. The ITA.LI.CA system performed better than other multidimensional prognostic systems, even after stratification by curative or palliative treatment. This new system appears to be particularly useful for predicting individual HCC prognosis in clinical practice. (HEPATOLOGY 2018;67: ) SEE EDITORIAL ON PAGE 2076 The prognostic classification of patients with hepatocellular carcinoma (HCC) is extremely difficult because overall survival is mutually influenced by the tumor burden, dysfunction of the underlying cirrhosis, and patient general conditions (i.e., performance status). (1-3) Several multidimensional prognostic systems have been proposed over the years. The Barcelona Clinic Liver Cancer (BCLC) classification is currently considered by American and European guidelines the best Abbreviations: AFP, alpha-fetoprotein; AIC, Akaike information criterion; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; CTPS, Child-Turcotte-Pugh score; COG-PST, Eastern Cooperative Oncology Group; EpaHCC, epatologia-hepatocellular carcinoma; HCC, hepatocellular carcinoma; HKLC, Hong Kong Liver Cancer; IQR, interquartile range; ITA.LI.CA, Italian Liver Cancer; JIS, Japan Integrated System; MESIAH, model to estimate survival in ambulatory patients with hepatocellular carcinoma. Received May 15, 2017; accepted November 14, Supported by the Associazione Italiana Gastroenterologi Ospedalieri [Italian Association of Gastroenterology Hospitals]. EpaHCC is an AIGO scientific project approved in 2008, and EpaHCC consortium includes AIGO members. AIGO is currently the owner of the EpaHCC electronic database. No formal AIGO grant has ever been funded to any member of this project. 2215
2 BORZIO ET AL. HEPATOLOGY, June 2018 system to predict survival in patients with HCC. (1-3) However, several studies have pointed out that this staging system has several prognostic limitations, mainly among patients belonging to BCLC stage B and C due to their heterogeneity (4) ; the controversial prognostic role of Eastern Cooperative Oncology Group (ECOG) performance status (PST), which can be influenced by liver function, cancer symptoms, or comorbidities other than cirrhosis (5) ; and the lack of statistical prognostic weighting attributed to different relevant factors, such as tumor status, liver function variables, and ECOG PST. (6,7) Recently, a multicenter Italian study group proposed a new prognostic system for patients with HCC, the Italian Liver Cancer (ITA.LI.CA) system. (8) Its main feature is to re-establish the prognostic centrality of tumor staging. In fact, the core component of the ITA.LI.CA prognostic system was defined as ITA.LI.CA tumor staging and was based on four main stages: 0, A, B, and C (Table 1). These stages are similar to the BCLC stages but were designed to have some relevant differences from the latter in order to avoid several confusing aspects: a) ITA.LI.CA stages were based only on tumor characteristics (i.e., ECOG PST and Child-Turcotte-Pugh (CTP) classes did not contribute to stage definition); b) single tumor >5cm was considered in the intermediate stage, regardless of the treatment received, and was based on published data and clinical knowledge. (4,6) Patients in B stage were further stratified into three substages, B1, B2, and B3 (Table 1); patients with HCC with extrahepatic vascular invasion or metastases were included only in stage C, while patients with intrahepatic vascular invasion were placed in stage B3. (4,9) The centrality of ITA.LI.CA tumor staging is important because it has the potential to be useful for therapeutic recommendations and designing clinical trials. However, as stated in the original paper, this tumor staging risks a suboptimal prognostic accuracy at an individual level because it does not consider liver function or patient general condition-related variables. (8) For these reasons, the authors integrated ITA.LI.CA tumor staging with the Child-Turcotte-Pugh score (CTPS), ECOG PST, and serum alpha-fetoprotein (AFP) values in a multivariable survival model. All these variables were statistically weighted to create a final 0-13 point score (ITA.LI.CA integrated prognostic system) for individual prognostic prediction (8) (Table 1). The ITA.LI.CA prognostic system was created using a strong statistical methodology in a large Italian cohort of patients (i.e., using training and validation sets) and then validated in an external large cohort from Taiwan. In the original paper, it performed better than other available systems. (8) However, for the introduction in the clinical practice of this system, its external validation in an independent study is strongly recommended. The aim of this study was to externally and independently Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI /hep Potential conflict of interest: Nothing to report. ARTICLE INFORMATION: From the 1 UOC Gastroenterologia ed Endoscopia Digestiva, ASST Melegnano e della Martesana, Milano, Italy; 2 Dipartimento di Medicina, SSVD di Epatologia, ASST Spedali Civili di Brescia, Brescia, Italy; 3 UOS Malattie delle vie Biliari e del Fegato, UOC malattie dell Apparato Digerente e del Fegato, AO S. Andrea, Universita Sapienza Roma, Roma, Italy; 4 UO Gastroenterologia e Malattie del Ricambio, Azienda Ospedaliero Universitaria Pisana, Ospedale Cisanello, Pisa, Italy; 5 Unita di Gastroenterologia, Ospedale Policlinico, Napoli, Italy; 6 UO Medicina VI Epatologia e Gastroenterologia, Ospedale San Paolo, Universita degli Studi di Milano, Milan, Italy; 7 Presidio Ospedaliero Pineta Grande, Unita di Ecointerventistica, Castel Volturno, Italy; 8 Dipartimento di Scienze Chirurgiche e Gastroenterologiche Ospedale Policlinico Padova, Padova, Italy; 9 Dipartimento di Medicina, Ospedale Santa Maria del Prato, Feltre, Italy; 10 UOS Gastroenterologia Ospedale di Bentivoglio, Bologna, Italy; 11 UO Gastroenterologia Ospedale Valduce, Como, Italy; 12 Dipartimento Medicina, Universita di Verona, Verona, Italy; 13 UOC Gastroenterologia, Ospedale S. Anna, Ferrara, Italy; 14 UO Medicina Interna I, Ospedale Civico e Benfratelli, Palermo, Italy; 15 Unita di Gastroenterologia ed Epatologia, Ospedale G da Saliceto, Piacenza, Italy. ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO: Mauro Borzio, M.D. Gastroenterology Unit ASST Melegnano e della Martesana, via Pandina 1, Vizzolo Predabissi Milan, Italy mauro.borzio@gmail.com Tel:
3 HEPATOLOGY, Vol. 67, No. 6, 2018 BORZIO ET AL. TABLE 1. The ITA.LI.CA Prognostic Score Score ITA.LI.CA tumor staging O A B1 B2 B3 C Diameter (cm) >5 3-5 >5 >5 any any Number of nodules >3 2-3 >3 any Any Vascular invasion or metastases no no no no no no no no intra extra Child-Turcotte-Pugh score ECOG performance status Serum AFP (ng/ml) 1,000 - >1,000 The score ranged from 0 to 13 points. The lowest score (ITA.LI.CA score 5 0) of the model corresponds to the best prognosis, and the highest score (ITA.LI.CA score 5 13) is associated with the worst prognosis. Tumor staging covers the highest prognostic span (from 0 to 5 points), CTPS and ECOG PST from 0 to 3, AFP from 0 to 2. validate the ITA.LI.CA prognostic system value in a large multi-institutional cohort of Western patients, mirroring HCC management in real life. Patients and Methods STUDY GROUPS We analyzed prospectively collected data of 1,508 consecutive patients with HCC who had been recruited between 2008 and April 2016 at 27 Italian institutions participating in the Hepatology-HCC (EpaHCC) project. EpaHCC is an ongoing multi-institutional, infield, large cohort of newly diagnosed HCCs created to specifically validate different prognostic systems of HCC. (10,11) In April 2016, the project enrolled 1,780 cases whose data had been entered in an ad hocdeveloped electronic database (Airon Telematica, Milan, Italy). At the time of this analysis, complete baseline and follow-up data were available in 1,580 cases. To avoid the risk of introducing a significant referral bias, centers for liver transplantation or specialized centers of hepatobiliary surgery were excluded from the study. Exclusion criteria were: a) HCC already present at the time this protocol was implemented (September 2008); b) human immunodeficiency virus co-infection; c) absence of cirrhosis or chronic liver disease. Only patients with a diagnosis of HCC confirmed either by histology or cytology or by typical radiologic appearance were included in the study group. (2,12) Clinical and treatment-related variables, such as age, sex, etiology of underlying liver disease, presence of ascites and hepatic encephalopathy, main serologic parameters (total bilirubin, creatinine, prothrombin time and/or international normalized ratio, AFP, albumin, platelet count), CTPS, (13) tumor radiologic characteristics (number and size of lesions), ECOG PST, (5) and main treatment strategy (hepatic resection, percutaneous ablation, intra-arterial therapies, or other options) were recorded. ECOG PST was prospectively assessed by clinicians who participated in the EpaHCC project. Tumor number and size, major vascular invasion, and patterns of metastatic diffusion were assessed by imaging (either computed tomography or magnetic resonance imaging). Vascular invasion was classified as intrahepatic and/or extrahepatic following the criteria of the Hong Kong Liver Cancer (HKLC) staging system. (6) In detail, intrahepatic vascular invasion included intrahepatic portal vein branch, left or right portal vein invasion, and main hepatic vein invasion; extrahepatic vascular invasion included main portal trunk and inferior vena cava invasion. No predetermined therapeutic protocols were operative, and clinical decisions regarding patient management were totally dependent on the current clinical practice of each participating center and by locally available resources. HCC treatment was classified in six main therapeutic options: liver transplantation, hepatic resection, ablation (percutaneous alcoholization, radiofrequency, or microwave), intra-arterial therapies, sorafenib, and others (other palliative treatment or best supportive care). Moreover, for each patient the following composite variables were calculated and recorded: BCLC classification, ITA.LI.CA prognostic score, HKLC staging, Cancer of the Liver Italian Program (CLIP) score, Japanese Integrated System (JIS), and model to estimate survival in ambulatory patients with hepatocellular carcinoma (MESIAH) score. (2,6-8,14,15) In particular, the ITA.LI.CA integrated prognostic score was calculated by a single formula, TSFA, where TS is the tumor stage (points from 0 to 5 for stages from 0 to C), F is the point value of the ITA.LI.CA functional score based on the CTPS and PST (0 points for CTPS of 5 and PST of 0, 2 points for CTPS of 6-7 and PST of 1-2 or CTPS of 8-9 and so on), and A is the AFP point value (0 points for AFP 1,000 ng/ml, 2 points for AFP >1,000 ng/ml) ( Table 1). Specifically, as exemplified in the original paper, the formula 2217
4 BORZIO ET AL. HEPATOLOGY, June 2018 A22 indicates a patient with stage A HCC with an ITA.LI.CA functional score of 2 and with 2 points for AFP, resulting in a final prognostic score of 5. (8) DESCRIPTIVE STATISTICS Baseline characteristics were examined based on frequency distribution; continuous data are presented as median (interquartile range) unless otherwise indicated. Univariate comparisons were assessed using the Student t test, Wilcoxon rank sum test, or chi-squared test as appropriate. Missing data relative to study covariates always involved less than 10% of patients; thus, they were imputed using the maximum likelihood estimation method. (16) Overall survival was defined as the time from the date of HCC diagnosis to the date of death, last follow-up evaluation, or data censoring (April 30, 2016). Kaplan- Meier survival curves were used to estimate the median, 1-, 3-, 5-, and 8-year overall survival. Survival curves were also stratified according to stage, and the log rank test was used to compare differences in survival. VALIDATION OF THE ITA.LI.CA PROGNOSTIC SYSTEM By using survival time as an outcome measure, important criteria for assessing the performance of any prognostic system were the following: 1) agreement between observed and predicted outcomes (calibration); 2) difference in survival time is small among patients classified into the same group by that system (homogeneity); 3) compared with this difference, there are much greater differences in the survival times among patients classified into different groups (discriminatory ability); and 4) mean survival time for a group classified as favorable by that system is always longer than the survival times noted in less favorable groups (monotonicity of gradients). (17) Calibration, homogeneity, discriminatory ability, and monotonicity of gradients were evaluated to measure the prognostic ability of the ITA.LI.CA prognostic system in comparison with that of other systems. (8) In testing calibration, patients were divided into quintiles at the 20 th,40 th,60 th and 80 th percentiles of the risk score. Calibration was defined as the graphic agreement between observed outcomes and predictions. (17) ITA.LI.CA quintiles were also used to graphically show the discriminatory ability of the ITA.LI.CA prognostic system over that of BCLC classification. The homogeneity, discriminatory ability, and the monotonicity of gradients in mortality rates of different prognostic systems were then described using the Akaike information criterion (AIC), the test for trend chi-square, and Harrell s C-index. (17) Briefly, the test for trend (which is more suitable than the log-rank test for measuring both the discriminatory power and monotonicity of gradients across categories) and the AIC test were used for measuring homogeneity. In the AIC test, we used the ordinary prognostic score rather than transforming it into dummy variables; thus, the AIC test can also estimate the monotonicity of gradients. Harrell s C-index, which requires no assumption of the model, represents the proportion of correct predictions or concordance in all possible pairs of patients. Suppose that in a given pair, patient A has a worse prognostic scorethanpatientb.ifthesurvivaltimeofaisshorter (longer) than that of B, the prediction is concordant (discordant) with the actual outcome. If, on the other hand, one patient is censored earlier than the time of death or census for the other patient, that pair is not counted. (17,18) A lower AIC value results in higher homogeneity and monotonicity of gradients of the staging system. A higher C-index and the test for trend chi-square result in higher discriminatory ability and monotonicity of gradients of the staging system. To measure whether the performance of the ITA.LI.CA score in terms of homogeneity, discriminatory ability, and monotonicity of gradients was significantly better than that of other systems, (2,6-8,14,15) we used the likelihood ratio test. Due to the heterogeneity of received treatments, a subgroup analysis for treatment category (i.e., curative versus palliative) was also performed to evaluate and overcome potential time-related biases. All statistical tests were based on the proportional hazards model. All analyses were carried out with STATA version 13.0 (Stata Corp, College Station, TX) and the JMP package ( ; SAS Institute Inc.). All tests were two-sided, and P < 0.05 was considered statistically significant. Results CHARACTERISTICS OF THE STUDY GROUP The characteristics of the study group are described in Table 2. The median age of enrolled patients was 71 years with a preponderance of male individuals (72.3%). 2218
5 HEPATOLOGY, Vol. 67, No. 6, 2018 BORZIO ET AL. TABLE 2. Patient Characteristics in the Study Group Variables Study Group (n 5 1,508) Sex M 1,091 (72.3%) F 417 (27.7%) Age (years) 71 (64-76) HBV (13.9%) HCV (55.2%) Alcohol abuse 319 (21.2%) Albumin (g/l) 35 (31-39) Bilirubin (mg/dl) 1.1 ( ) INR 1.2 ( ) Platelets 114 (81-167) Creatinin (mg/dl) 0.9 ( ) Presence of ascites 341 (22.6%) Presence of encephalopathy 82 (5.4%) Child-Turcotte-Pugh score 6 (5-7) MELD 7 (6-11) ECOG PST (62.0%) (25.1%) (8.7%) (4.2%) AFP (ng/ml) 14 (5-88) Diameter of largest lesion (mm) 30 (21-50) Multinodular (>3 nodules) 260 (17.2%) Macrovascular invasion 222 (14.7%) Intrahepatic 125 (8.3%) Extrahepatic 97 (6.4%) Presence of metastases 56 (3.7%) BCLC stage (8.2%) A 687 (45.5%) B 310 (20.6%) C 276 (18.3%) D 111 (7.4%) ITA.LI.CA Tumor stage (16.3) A 472 (31.3) B1 371 (24.6) B2 116 (7.7) B3 170 (11.3) C 133 (8.8) Main treatment Resection 157 (10.4%) Transplantation 17 (1.1%) Ablation 490 (32.5%) IAT 416 (27.6%) Sorafenib 68 (4.5%) Other/BSC 360 (23.9%) (16.3%), 472 in the early stage (31.3%), 657 in the intermediate stages (B1 24.6%, B2 7.7%, B3 11.3%), and 133 in the advanced stage (8.8%) (Fig. 1). Surgery was carried out in 174 patients (liver transplantation 1.1%, hepatic resection 10.4%), ablation in 490 (32.5%), intraarterial therapy in 416 (27.6%), sorafenib in 68 (4.5%), and other palliative therapy/best supportive care in 360 (23.9%). The overall adherence to the BCLC therapeutic algorithm was 56.6%; in particular, adherence to the BCLC algorithm was 65% for liver transplantation, 65% for resection, 66% for ablation, 56% for transarterial chemoembolization, and 73% for sorafenib. The lowest adherence rate was registered for other palliative treatments or best supportive care (36%). CALIBRATION OF THE ITA.LI.CA PROGNOSTIC SYSTEM Median duration of follow-up was 44 months (interquartile range, months). Median overall survival was 34 months (interquartile range, months), and the 1-, 3-, and 5-year overall survival rates were 78%, 48%, and 34%, respectively. The lowest ITA.LI.CA score (score 5 0) corresponded to the best prognosis, whereas the highest score (score 5 13) was associated with the worst prognosis (Table 3; P < , log-rank test). To test the prognostic calibration of the ITA.LI.CA score, patients were divided into quintiles at the 20 th,40 th, 60 th, and 80th percentiles of the risk score. Quintile 1 Abbreviations: BSC, best supportive care; IAT, intra-arterial therapy; INR, international normalized ratio; MELD, model for end stage liver disease. The majority of patients were hepatitis C carriers (55.2%), whereas only a minority of patients were hepatitis B carriers (13.9%). A non-negligible proportion of the study cohort (31.1%) had decompensated cirrhosis (CTPS, B-C) and 38% had an ECOG PST >0. In terms of tumor characteristics (i.e., ITA.LI.CA tumor staging), 246 patients were in the very early stage FIG. 1. Expected versus observed survival in the study cohort (calibration). Patients were divided into quintiles at the 20 th, 40 th,60 th, and 80 th percentiles of the risk score. Q1 coincided with ITA.LI.CA score 1, Q2 with score 2, Q3 with score 3-4, Q4 with score 5-6, and Q5 with values >
6 BORZIO ET AL. HEPATOLOGY, June 2018 Score TABLE 3. Discrimination Ability of Different HCC Prognostic Systems Number of Patients (%) Observed Median Survival (Months) Lower 95% Higher 95% All 1, ITA.LI.CA score (8) (7.8) (17.9) (19.8) (15.8) (11.0) (8.0) (5.0) (8.7) (4.4) (1.5) CLIP (13) (41.1) (28.0) (17.8) (8.8) (4.4) HKLC (6) I 608 (40.3) IIa 304 (20.2) IIb 179 (11.9) IIIa 38 (2.5) IIIb 26 (1.7) IVa 75 (5.0) IVb 56 (3.7) Va 110 (7.3) Vb 112 (7.4) MESIAH (7) Q1 375 (24.9) Q2 376 (24.9) Q3 380 (25.2) Q4 377 (25.0) JIS (14) (10.0) (38.7) (21.6) (17.2) (9.2) (3.3) BCLC (2) (8.2) A 687 (45.5) B 310 (20.6) C 276 (18.3) D 111 (7.4) Distribution of patients in different points/stages of the prognostic systems and corresponding observed median survivals. Log-rank test, P < (Q1) coincided with ITA.LI.CA score 1, quintile 2 (Q2) with score 2, quintile 3 (Q3) with score 3-4, quintile 4 (Q4) with score 5-6, quintile 5 (Q5) with values >6 (Fig. 1). The calibration of the ITA.LI.CA prognostic system was clearly shown to be optimal in the study cohort because predicted and observed median survivals and survival curves largely coincided for each quintile of the enrolled population (Fig. 1). HOMOGENEITY, DISCRIMINATION, AND MONOTONICITY OF GRADIENTS OF THE ITA.LI.CA PROGNOSTIC SYSTEM To evaluate the discriminatory power of the ITA.LI.CA system, we first described its prognostic 2220
7 HEPATOLOGY, Vol. 67, No. 6, 2018 BORZIO ET AL. FIG. 2. Kaplan-Meier survival curve of the study group stratified according to BCLC stages. Log-rank test, P < 0.001; AIC, 7,421; C-index ability by Kaplan-Meier survival curves according to BCLC and ITA.LICA quintiles (Figs. 2 and 3). The discriminatory ability of the ITA.LI.CA score was better than that of BCLC (AIC, 7,421 for BCLC; AIC, 7,232 for ITA.LI.CA). The discriminatory ability of the ITA.LI.CA system compared with that of other available systems is shown in Table 3.When the ITA.LI.CA prognostic score was considered (from 0 to 13 points), it showed the best homogeneity, discriminatory ability, and monotonicity of gradients among the most common HCC staging systems (Table 4). In particular, the C statistic of the ITA.LI.CA score in the whole study group was 0.77, a value superior to that of the BCLC (0.74), CLIP (0.73), JIS (0.74), MESIAH (0.76), and HKLC (0.75). By using the likelihood ratio test to compare different survival models, the prognostic performance of the ITA.LI.CA system resulted once again as better than that of other systems (P < ). The superiority of the ITA.LI.CA score was also confirmed after stratification of the patient population for treatment strategy (curative versus palliative). Only the MESIAH score showed a prognostic performance not significantly inferior to the ITA.LI.CA score (P ) in patients undergoing curative therapies (i.e., surgery and ablation). Discussion Prognostic staging of HCC is still a challenge. (1-4) Several staging systems have been proposed, but none have been universally adopted. The difficulties in constructing an optimal staging system rely on the fact that the outcome of HCC is a composite result mutually influenced by tumor burden, residual function related to the underlying liver cirrhosis, and the general health status (i.e., performance status). (1-4) In addition, differences in epidemiology and risk factors for HCC in different geographic areas further account for these difficulties and may explain why several validation studies aimed at comparing the prognostic performance of different staging systems yielded conflicting results. (19-21) Recently the ITA.LI.CA group proposed a new prognostic system, the ITA.LI.CA system, integrating a tumor staging (six main stages: 0, A, B1, B2, B3, and C), a functional prognostic score (based on CTPS and ECOG-PST), and AFP. In the original paper, the ITA.LI.CA system was superior to other multidimensional systems in predicting survival in an internal validation cohort (ITA.LI.CA cohort) and in an external one from Taiwan. (8) In the present study, we proposed the first external and independent validation of the ITA.LI.CA prognostic system in a large real-life Italian cohort (EpaHCC multi-institutional cohort) of newly diagnosed HCCs. In our cohort, the ITA.LI.CA prognostic system offered the best predictive ability in terms of calibration, homogeneity, discriminatory ability, and monotonicity of gradients. (17) The rigorous statistical methodology by which this system was originally FIG. 3. Kaplan-Meier survival curve of the study group stratified according to ITA.LI.CA quintiles. Log-rank test, P < 0.001; AIC, 7,232; C-index
8 BORZIO ET AL. HEPATOLOGY, June 2018 TABLE 4. Discrimination Ability and Monotonicity of Gradients of Different HCC Prognostic Systems HCC Prognostic System AIC C-Index v 2 Test LR Test, P Value Study group (n 5 1,508) ITA.LI.CA score (8) 7, CLIP (13) 7, , < HKLC (6) 7, , < MESIAH (7) 7, , < JIS (14) 7, , < ITA.LI.CA tumor stage (8) 7, , < BCLC (2) 7, , < Curative treatment (n 5 658) ITA.LI.CA score (8) 2, CLIP (13) 2, , HKLC (6) 2, , MESIAH (7) 2, , JIS (14) 2, , ITA.LI.CA tumor stage (8) 2, , < BCLC (2) 2, , Noncurative treatment (n 5 850) ITA.LI.CA score (8) 4, CLIP (13) 4, , < HKLC (6) 4, , MESIAH (7) 4, , < JIS (14) 4, , < ITA.LI.CA tumor stage (8) 5, , < BCLC (2) 4, , < Each column shows the AIC, C-index, and test for trend chi-square. The lower the AIC value, the higher the homogeneity and the monotonicity of gradients of the prognostic system; the higher the C-index and the test for trend chi-square, the higher the discriminatory ability and monotonicity of gradients of the prognostic system. In addition, in each column the ITA.LI.CA score was compared with other systems by using the likelihood ratio test. Abbreviation: LR, likelihood ratio. elaborated (8) may account for its superiority over the other five multidimensional prognostic systems considered in this study (Tables 3 and 4). In particular, the ITA.LI.CA system performed better than the BCLC system. This finding is not surprising and parallels the observations reported in two recent comparative studies carried out on Eastern and Western cohorts of HCC. These studies were aimed at comparing the accuracy of different prognostic systems, and the BCLC system performed less well than the CLIP score, which ranked first. (19,20) The relatively unsatisfying predictive ability of the BCLC classification is probably due to this system being mainly based on data extrapolated from systematic reviews of the literature and/or expert opinions rather than developed by a solid statistical methodology. The ITA.LI.CA system was also superior to the HKLC system in defining the prognosis of our Western population of HCC. This is possibly due to the epidemiologic characteristics of the large Asiatic population on which this latter system was developed (mostly composed of patients infected by the hepatitis B virus [HBV] (6) ). Indeed, the HKLC system is still waiting for a robust validation in Western countries, and its accuracy has been challenged. (22) However, to further increase robustness and exportability of ITA.LI.CA, new independent validations (from different authors) should be performed in the Eastern world where HBV-related HCC is prevalent. These validation studies are highly warranted and should be carried out in the near future. In the present study, the ITA.LI.CA integrated prognostic score confirmed a high calibration ability. In particular, the expected and observed survival in different score quintiles showed strict correspondence, a finding well in keeping with the findings of the original paper (Fig. 1). The performance of any HCC staging system should be interpreted within the specific context in which it was created. Therefore, a full characterization of the examined study population should anticipate the validation process. The ITA.LI.CA and EpaHCC cohorts are comparable as far as median age, etiology of cirrhosis, BCLC stratification, treatment offered, adequate follow-up, and median overall survival are concerned. (8) Moreover, both cohort characteristics are in line with the inherent characteristics of most of the Caucasian cohorts for which other staging systems were tested and validated and strictly reflect the life 2222
9 HEPATOLOGY, Vol. 67, No. 6, 2018 BORZIO ET AL. scenario of HCC distribution and management in most European countries. (2) We thus believe that our findings further reinforce the strength and exportability of our validation data. An additional advantage provided by the use of the EpaHCC cohort to validate the ITA.LI.CA system is its representativeness of the current presentation and management of HCC. Indeed, accrual of the EpaHCC cohort started in 2008, while the ITA.LI.CA cohort accrual period covered a larger time span ( ) This aspect is not trivial because EpaHCC strongly adds homogeneity in terms of current diagnostic and treatment options, thus limiting the potential for time-related selection bias. Although the BCLC and ITA.LI.CA systems share a comparable tumor-staging framework, some relevant differences between the two systems deserve mention. First, unlike BCLC, in this new system, tumor stages are based only on oncologic characteristics while ECOG PST and CTPS are not considered. This may, at least in part, overcome the well-known limits of including these two variables when not weighted in a multivariable survival model. Second, ITA.LI.CA tumor stage 0 (Table 1) is clearly defined as a single nodule 2 cm. Conversely, the BCLC stage 0 definition (23) only recently included a single nodule 2cm, while previous definitions in guidelines (2,3) included single nodules <2 cm. Third, in an attempt to overcome the limits posed by the large heterogeneity of patients belonging to the BCLC intermediate stage and in keeping with a recent proposal, the ITA.LI.CA system further divided the ITA.LI.CA stage into three substages: B1, B2, and B3. Fourth, the ITA.LI.CA system simplified the stratification of patients harboring large HCC (>5 cm as a threshold), emending the confounding concept of resectability. Fifth, the presence of vascular invasion was better defined dividing thrombosis into intrahepatic and extrahepatic forms, resulting in a more precise calibration of the whole system. Finally, AFP was added to the prognostic score; this marker was used as a categorical variable rather than a continuous one with a cutoff >1,000 ng/ml because this value yielded the best prognostic power in the original survival model from Farinati et al. (8) Treatment per se is also a strong predictor of HCC outcome. Consequently, international guidelines recommend the use of multidimensional systems linking staging with treatment decisions. (2,3) However, treatment for HCC in cirrhosis is complex, varying widely among different geographic areas and with several therapeutic options being available for each stage. In addition, the high heterogeneity of patients included in any given stage, especially in BCLC intermediate/advanced ones, implies a wide range of possible managing treatments (including no treatment) with a consequent potential for a wide variation of their impact on overall survival. Rigidity of the BCLC therapeutic algorithm as well as its difficulty to be applied in clinical practice have been repeatedly underlined. (10,24) For these reasons, Farinati et al. (8) decided not to include a prefixed treatment algorithm in their integrated prognostic system. However, in contrast to the original study, we tested the prognostic performance of the ITA.LI.CA prognostic score in patients stratified by curative or palliative treatment. The ITA.LI.CA prognostic system performed better than other systems in patients undergoing curative and those undergoing palliative therapy. In patients treated by curative therapies, the MESIAH score also displayed a good predictive ability with only a marginally significant statistical difference (P ) between the ITA.LI.CA and MESIAH score. However, the main limit of the MESIAH score is that it does not offer tumor staging to guide and assist treatment decisions. (7) Conversely, we did not perform this analysis in single-therapy subgroups for two main reasons: 1) Some treatment subgroups (i.e., liver transplantation, resection, sorafenib) were too small to test the prognostic power of staging systems. 2) All HCC prognostic systems have been developed and designed for general HCC populations, including all different therapeutic options. Consequently, we considered that it was not appropriate to test them as single-therapy subgroups. A limitation of the present study is its retrospective nature. However, one of the most stringent prerequisites required from each participating center to the EpaHCC project was the consecutive enrollment of patients, and the EpaHCC database was specifically created to validate different prognostic systems in clinical practice. Consequently, each patient at entry was stratified according to staging systems available at that time and followed thereafter. Individual records entered into the database made it possible to stratify patients according to the ITA.LI.CA system as well. These methodologic precautions contribute to minimizing the inherent biases of retrospective studies. Another limitation is that the present study could not fully assess the role that different treatments for different stages might have had on overall survival. Therefore, further studies are warranted to validate the prognostic value of this scoring system in other welldesigned prospective cohorts. 2223
10 BORZIO ET AL. HEPATOLOGY, June 2018 A final limitation of this study is that the variable antiviral therapy for both HBV and hepatitis C virus (HCV) cases was not provided in the EpaHCC database. In particular, in light of the recent introduction of new anti-hcv therapies and their suspected negative role on HCC outcome, (25) the EpaHCC database will be improved by adding antiviral therapy information to analyze its prognostic impact. In conclusion, our study provides a robust validation of the integrated ITA.LI.CA prognostic system in a large, real-life, occidental cohort of HCC (EpaHCC multi-institutional cohort). In our prospective cohort in which HCV-related HCC is prevalent, the ITA.LI.CA prognostic score was accurate in predicting HCC outcome and performed better than the other staging systems considered. In addition, the predictive accuracy of the ITA.LI.CA system was maintained in both treated and untreated patients. This newly developed staging system has thus several advantages over the other commonly used multidimensional prognostic systems, making it more suitable for HCC prognostication at an individual level. Acknowledgment: The present study was sponsored by the Associazione Italiana Gastroenterologi Ospedalieri. Other members of the EpaHCC group are the following: UOC Gastroenterologia, ATSS Melegnano-Martesana, Italy: Dr.ssa R. Ferrini, Dr.ssa M. Quagliuolo; UO Gastroenterologia, Ospedale Valduce, Italy: Dr. G. Spinzi; Ospedale S. Maria del Prato, Italy: Dr. G. Parisi, Dr. M. Tollardo, Dr. C. Cardaioli; UO Medicina, Ospedale di Gavardo, Italy: Dr.ssa O. Bonzanini, Dr.ssa S. Polo; Ospedale Alessandro Manzoni Struttura Complessa di Medicina Generale, Italy: Dr. M. Andreoletti; Ospedale Fatebenefratelli, UO di Ecografia, Centro Zerbi, Radiologia, Milano, Italy: Dr. F. Borzio; UO Gastroenterologia ed Endoscopia Digestiva Ospedale San Carlo Borromeo Milano, Italy: Dr. A. Capretti; Cattedra di Gastroenterologia Seconda Universita di Napoli, Ospedale Policlinico, Italy: Dr. Niosi; Dipartimento Scienze Chirurgiche e Gastroenterologiche, Policlinico Universitario Padova, Italy: Dr.ssa A. Giacomin; UO Medicina Interna I, Ospedale Civico e Benfratelli, Palermo, Italy: Dr. A. Maranghini; Servizio di Gastroenterologia ed endoscopia ASL2 PG, Italy: Dr..ssa F. Sannella, Dr. A. Solinas; UO Gastroenterologia, Ospedale SS Cosma e Damiano, Pescia, Italy: Dr. P. Montalto; UOC Gastroenterologia ed Epatologia Ospedale G. da Saliceto, Piacenza, Italy: Dr. G.M. Prati, Dr.ssa P. Perazzo; UO Gastroenterologia Azienda Ospedaliera G.Salvini Ospedale di Rho, Italy: Dr.ssa A. Bortoli, Dr. A. Prada; UO Gastroenterologia, Ospedale Infermi, Rimini, Italy: Dr.ssa A. Miracolo, Dr. D. Onorato, Dr. L. Solmi; Azienda Ospedaliera S. Andrea, Roma, Italy: Dr.ssa P. Begini, Dr.ssa G. Anania; UO Gastroenterologia, San Giovanni Rotondo, Italy: Dr.ssa F. Terracciano, Dr. A. Andriulli; SC Gastroenterologia ed Epatologia, Presidio Sanitario Gradenigo, Italy: Dr. F. Rosina, Dr.ssa M. Berruti; UO Gastroenterologia, Ospedale San Bortolo, Vicenza, Italy: Dr. M. Salvagnini, Dr. A. D Alessandro; Ospedale di Vizzolo-Predabissi, ATSS Melegnano- Martesana, Medicina Epatologia, Italy: Dr. R. Centenaro; Dipartimento di Medicina, Chirurgia ed Odontoiatria, Ospedale San Paolo, Universita degli Studi di Milano, Italy: Dr. M. Zuin. REFERENCES 1) Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35: ) European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL- EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56: ) Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. HEPATOLOGY 2005;42: ) Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32: ) Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. HEPATOLOGY 2013; 57: ) Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146: ) Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. HEPATOLOGY 2012;56: ) Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, et al.; ITA.LI.CA study group. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. PLoS Med 2016;13:e
11 HEPATOLOGY, Vol. 67, No. 6, 2018 BORZIO ET AL. 9) United Network for Organ Sharing. Important policy notice Dec policies.pdf#nameddest5policy_09. Accessed March, ) Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, et al.; EpaHCC Group. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol 2013;9: ) Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, et al. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience. Dig Dis Sci 2015;60: ) Italian Association for the Study of the Liver (AISF); AISF Expert Panel; AISF Coordinating Committee, Bolondi L, Cillo U, Colombo M, Craxı A, Farinati F, Giannini EG, et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liv Dis 2013;45: ) Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60: ) [No authors listed]. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. HEPATOLOGY 1998;28: ) Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38: ) Baraldi AN, Enders CK. An introduction to modern missing data analyses. J Sch Psychol 2010;48: ) Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21: ) Stone M. Akaike s criteria. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Chichester, United Kingdom: Wiley;1998: ) Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, et al Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol 2016:64; ) op dev Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, et al. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. Plos One 2012;7:e ) Maida M, Orlando E, Camma C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20: ) Adhoute X, Penaranda G, Bronowicki JP, Raoul JL. Usefulness of the HKLC versus. the BCLC staging system in a European HCC cohort. J Hepatol 2015;62: ) Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016;150: ) Leoni S, Piscaglia F, Serio I, Terzi E, Pettinari I Croci L, et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. Dig Liv Dis 2014;46: ) Alberti A, Piovesan S. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: fact or fiction? Liver Int 2017;37:
Staging and prognostic systems: beyond BCLC?
Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationINTRODUCTION. Key Words: Carcinoma, hepatocellular; Barcelona Clinic Liver Cancer; Hong Kong Liver Cancer; Neoplasm staging.
Gut and Liver, Vol. 12, No. 1, January 218, pp. 94-11 ORiginal Article Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationOptimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study
Su et al. BMC Cancer (2016) 16:424 DOI 10.1186/s12885-016-2420-0 RESEARCH ARTICLE Open Access Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationDeterminants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice I-Cheng Lee, MD, PhD, Yi-Tzen Chen, RN, Yee Chao, MD, Teh-Ia Huo, MD, Chung-Pin
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationHepatocellular carcinoma: Intra-arterial treatments
Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA
More informationRESEARCH ARTICLE. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6929 Real-Life HCC Treatment - Influence on Outcome of Deviation from Therapy Guidelines RESEARCH ARTICLE Real Life Treatment of Hepatocellular Carcinoma:
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationAggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases
RESEARCH ARTICLE Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases Ashraf Omar Abdel Aziz 1, Dalia Omran
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationHepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationONCOLOGY LETTERS 15: , 2018
ONCOLOGY LETTERS 15: 855-862, 2018 Comparison of five staging systems in predicting the survival rate of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization therapy ZHAN
More informationChanging epidemiology of HCC in Italy
Changing epidemiology of HCC in Italy G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche-Trapianto di Fegato Università Politecnica delle Marche, Ancona Worldwide estimated new PLC
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationSurgical resection for hepatocellular carcinoma (HCC)
Surgical resection for hepatocellular carcinoma (HCC) Wojciech G Polak, MD, PhD, FEBS Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam the
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular
More informationNomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
doi: 10.2169/internalmedicine.9064-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationUsing nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma
Hsu et al. BMC Cancer (2018) 18:289 https://doi.org/10.1186/s12885-018-4202-3 RESEARCH ARTICLE Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationSIRTEX Lunch Symposium, Cebu, 23 Nov Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong
SIRTEX Lunch Symposium, Cebu, 23 Nov 2013 Dr. Stephen L. Chan Department of Clinical Oncology The Chinese University of Hong Kong I will not talk on Mechanism of SIRT Data on efficacy of SIRT Epidemiology
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationTACE: coming of age?
Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationCIRROSI E IPERTENSIONE PORTALE NELLA DONNA
Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di
More informationORIGINAL ARTICLE LIVER TRANSPLANTATION 21: , Additional supporting information may be found in the online version of this article.
LIVER TRANSPLANTATION 21:1250 1258, 2015 ORIGINAL ARTICLE Utility-Based Criteria for Selecting Patients With Hepatocellular Carcinoma for Liver Transplantation: A Multicenter Cohort Study Using the Alpha-Fetoprotein
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationCirrhotic patients with solitary hepatocellular carcinoma
ORIGINAL ARTICLES Survival of Cirrhotic Patients With Early Hepatocellular Carcinoma Treated by Percutaneous Ethanol Injection or Liver Transplantation Angelo Andriulli, 1 Ilario de Sio, 2 Luigi Solmi,
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationCost-Effectiveness of Sorafenib Treatment in Field Practice for Patients With Hepatocellular Carcinoma
Cost-Effectiveness of Sorafenib Treatment in Field Practice for Patients With Hepatocellular Carcinoma Calogero Cammà, 1 Giuseppe Cabibbo, 1 Salvatore Petta, 1 Marco Enea, 2 Massimo Iavarone, 3 Antonio
More informationHepatology. The critical issue of hepatocellular carcinoma restaging: which is the best tool available?
The critical issue of hepatocellular carcinoma restaging: which is the best tool available? Journal: Manuscript ID HEP-- Wiley - Manuscript type: Rapid Communication Date Submitted by the Author: -Dec-0
More informationORIGINAL ARTICLE. Jun Zheng 1, Rong-chun Xing 1, Wei-hong Zheng 2, Wei Liu 1, Ru-cheng Yao 1, Xiao-song Li 1, Jian-ping Du 1, Lin Li 1.
JBUON 2017; 22(3): 709-713 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A comparative study on postoperative mortality prediction of SFLI scoring
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More information21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?
Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional
More informationHepatocellular carcinoma (HCC) is a highly. Prognosis of Untreated Hepatocellular Carcinoma
Prognosis of Untreated Hepatocellular Carcinoma Edoardo G. Giannini, 1 Fabio Farinati, 2 Francesca Ciccarese, 3 Anna Pecorelli, 4 Gian Lodovico Rapaccini, 5 Mariella Di Marco, 6 Luisa Benvegnu, 7 Eugenio
More informationAlbumin-to-bilirubin score for assessing the in-hospital death in cirrhosis
Original Article Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis Lichun Shao 1 *, Bing Han 1 *, Shu An 2, Jiaxin Ma 1, Xiaozhong Guo 3, Fernando Gomes Romeiro 4, Andrea Mancuso
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationPercutaneous ablation: indications, techniques and results
Percutaneous ablation: indications, techniques and results Giovan Giuseppe Di Costanzo Dipartimento dei Trapianti UOSC Epatologia AORN A Cardarelli - Napoli Treatment algorithm EASL, EORTC guidelines HCC
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationUPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA
UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the
More informationCHIRURGIA EPATOBILIARE IN WEEK SURGERY?
U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici Università degli Studi di Padova CHIRURGIA EPATOBILIARE IN WEEK SURGERY? Umberto Cillo, MD, PhD, FEBS cillo@unipd.it Quali sono gli ingredienti
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationEditorial Process: Submission:07/25/2018 Acceptance:10/19/2018
RESEARCH ARTICLE Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand Jitrapa
More informationTreatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories
Original Research 987 Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories Kuan-Ling Kuo, PhD a ; David Stenehjem, PharmD a,b ; Frederick
More informationCOMPARATIVE EFFECTIVENESS OF SURVEILLANCE AND CURRENT TREATMENT APPROACHES FOR THE DETECTION AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA IN EAST ASIA
COMPARATIVE EFFECTIVENESS OF SURVEILLANCE AND CURRENT TREATMENT APPROACHES FOR THE DETECTION AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA IN EAST ASIA Diana R. Chirovsky A dissertation submitted to the faculty
More informationTreatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study
Published online: September 16, 2017 Original Paper Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Clarence
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationPercutaneous Ethanol Injection Therapy in the Treatment of Hepatocarcinoma Results Obtained from a Series of 88 Cases
Percutaneous Ethanol Injection Therapy in the Treatment of Hepatocarcinoma Results Obtained from a Series of 88 Cases Mirela Danila, Ioan Sporea, Roxana Sirli, Alina Popescu Department of Gastroenterology
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationScreening for hepatocellular carcinoma (HCC) is controversial.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:508 512 Screening for Hepatocellular Carcinoma Among Veterans With Hepatitis C on Disease Stage, Treatment Received, and Survival LUCI K. LEYKUM,* HASHEM
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationMULTIMODALITY TREATMENT OF HEPATOCELLULAR CARCINOMA: HOW FIELD PRACTICE COMPLIES WITH INTERNATIONAL RECOMMENDATIONS
DR. ANGELO SANGIOVANNI (Orcid ID : 0000-0002-9996-9385) DR. MASSIMO IAVARONE (Orcid ID : 0000-0003-3493-6504) DR. VINCENZO LA MURA (Orcid ID : 0000-0003-4685-7184) PROF. MASSIMO GIUSEPPE COLOMBO (Orcid
More informationSaudi Gastroenterology Association Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Summary of Recommendations
Special Communication Saudi Gastroenterology Association Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Summary of Guidelines Editors: Ayman A Abdo, Huda Al Abdul Karim, Turki
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationDevelopment of a prognostic scoring system for resectable hepatocellular carcinoma
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v22.i36.8194 World J Gastroenterol 2016 September 28; 22(36): 8194-8202 ISSN 1007-9327
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More information